Hansenula polymorpha

BTR is proud to offer its clients access to one of the premier expression systems in use today, Hansenula polymorpha. Worldwide exclusive licensing rights for this yeast technology covering various application fields are held by Artes Biotechnology of Germany. Artes and BTR are co-operating to make this technology available to you.

Advantages of the Hansenula System:
	Stable Strains
	Multi-copy strains with up to 150 copies per cell Co-expression of up to 4 different genes
	Short, Flexible Fermentations
	Wide range of cultivation conditions Inexpensive media without methanol
	Cost-Effective Product Recovery
	Low levels of impurities High productivity: 13.5 g/L obtained High product stability, low protease activity
	Reliable, Secure Process
	High batch-to-batch reproducibility Strong patent protection Proven technology

Commercial Successes of Hansenula

A number of products currently on the market have proven the value of Hansenula technology, including a recombinant Hepatitis B vaccine produced from Hansenula. It is the first registered pharmaceutical product derived from a methylotrophic yeast world-wide. Hansenula also holds the record in yeast derived-protein production, with a productivity of more than 13 g/L in phytase production. Several other industrial products are marketed by licensees making use of the economically advantageous features of Hansenula. In 2002, a Hansenula-derived recombinant enzyme received GRAS status from the FDA.

For more detailed technical information, literature updates and the latest news related to the Hansenula technology, please visit www.artes-biotechnology.com.

Using the Hansenula Technology

Hansenula polymorpha requires relatively simple cultivation and scale-up processes. High product yields are achieved through high gene copy integration, fast growth to high cell density, and an exclusive library of strong promoters. Hansenula works well for either single or multi-step biocatalytic conversions. With this system you can produce high concentration of recombinant product using low-cost culture medium.

Research licenses are accompanied by intense training and are uncoupled from commercialization. Commercial licenses are also available with terms negotiable according to business application.

For more information, contact Julie Maurina-Brunker (julie@biotechresources.com or 920-684-5518) or visit the following pages: "Hansenula for Maximum Yield" and "Hansenula for System Versatility."

Top